JESSICA NGUYEN-BINDER: Open Payments
NPI 1801162466 · BALTIMORE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$360 in 20 payments from 9 companies in 2025. Trend: 2023 $195 · 2024 $257 · 2025 $360
Food & beverage: $360
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 4 | $70 |
| Lilly USA, LLC | 3 | $69 |
| Amgen Inc. | 4 | $61 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $36 |
| GlaxoSmithKline, LLC. | 2 | $34 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $32 |
| Phathom Pharmaceuticals, Inc. | 1 | $22 |
| Merck Sharp & Dohme LLC | 1 | $18 |
| AstraZeneca Pharmaceuticals LP | 1 | $18 |
Products named: REXULTI, JARDIANCE, Kerendia, XIFAXAN, OTEZLA, VOQUEZNA, AREXVY, GARDASIL 9.
Industry payments across MD — which companies pay providers there.
